The science at the heart of the study is thromboelastography, or TEG, a technique that goes far beyond the standard clotting time measured in routine coagulation panels. Instead of asking merely how long blood takes to clot, TEG measures the viscoelastic properties of a clot as it forms in a small cup of whole blood, tracking how quickly it develops, how strong it becomes, and how stable it remains. The headline parameter in this research is the maximum amplitude, abbreviated MA, which reflects the ultimate strength of the clot and depends heavily on platelet function and platelet-fibrin interactions. A higher MA signals a stiffer, more robust clot, a profile that clinicians describe as procoagulant or hypercoagulable. In patients with type 2 diabetes, previous work has associated testosterone deficiency with just such a procoagulant TEG signature, raising the question of whether the hormonal milieu more broadly, rather than testosterone in isolation, shapes clot behavior.

That question led the study’s author, Xiao-Jun Chen of the Department of Endocrinology at Shanghai Tenth People’s Hospital’s Chongming Branch and Anting Hospital in Shanghai, to examine the estradiol-to-testosterone ratio, calculated by dividing serum estradiol in picomoles per liter by total testosterone in nanomoles per liter. Estradiol, often thought of as a female hormone, is present in men as well, both produced directly and converted from testosterone through the enzyme aromatase. Because this conversion means estradiol and testosterone are biochemically intertwined, some investigators have proposed that the ratio between them may capture a more nuanced picture of relative androgen-estrogen balance than either hormone measured alone. Whether that added nuance translates into additional information about thrombosis risk has remained uncertain, and it is precisely the gap this analysis set out to probe.

The study population consisted of 92 hospitalized men with type 2 diabetes drawn from a previously published single-center cohort, with complete TEG data available for 84 of them. All participants had provided written informed consent under a protocol approved by the Ethics Committee of Chongming Branch, Shanghai Tenth People’s Hospital, and conducted in accordance with the Declaration of Helsinki. Clot testing was performed on a TCA-6000 analyzer using citrated whole blood with kaolin activation, a standard configuration in routine TEG work. The median estradiol-to-testosterone ratio in the cohort was 10.92, with an interquartile range spanning 5.97 to 17.23, indicating substantial variability in hormonal balance even within this relatively homogeneous group of diabetic men.

The first striking result emerged when participants were sorted into tertiles, or thirds, according to their hormone ratio. Across increasing tertiles of estradiol-to-testosterone, the median TEG maximum amplitude climbed steadily from 59.4 to 62.4 and then 65.9 millimeters, a graded relationship that reached statistical significance at P equal to 0.002. In other words, men whose blood showed a relatively higher estrogen signal compared with testosterone tended to form measurably stronger clots. Because MA is a direct readout of clot firmness, this pattern hints that a shift in hormonal balance toward relatively more estrogenic activity might accompany a more procoagulant state in diabetic men, though a cross-sectional snapshot like this cannot establish which way any causal arrow would point.

To test whether the association could survive statistical scrutiny, the analysis turned to multivariable linear regression, adjusting for age, body mass index, glycated hemoglobin, and fasting glucose, the usual suspects that might otherwise confound a hormone-clot relationship. After natural-log transformation of the ratio, the adjusted model estimated that each unit increase in log-transformed estradiol-to-testosterone was associated with a 2.85 millimeter increase in maximum amplitude, with a 95 percent confidence interval of 0.85 to 4.85. The conventional P value was 0.006, and the result held up under more demanding statistical treatment: a false-discovery-rate correction yielded an adjusted P of 0.024, and heteroscedasticity-consistent HC3 standard errors, which guard against uneven variability in the data, produced a P of 0.021. For an exploratory secondary analysis, that level of robustness is notable.

What truly distinguishes the study, however, is the battery of sensitivity analyses deployed to make sure the finding was not an artifact of a single influential data point or a fragile modeling choice. The researchers excluded the participant with the maximum estradiol-to-testosterone value, and the estimate not only survived but grew slightly, to 3.40 with an HC3 P of 0.014. Winsorization, a technique that caps extreme values rather than deleting them, left the association intact at 3.00 with a P of 0.017. Screening out observations with excessive influence by Cook’s distance, a diagnostic that flags data points capable of distorting a regression, gave an estimate of 3.29 with a P of 0.002. Most convincingly, a leave-one-out procedure refit the model 84 separate times, each time removing a different participant, and the coefficient stayed positive in every refit, ranging from 2.36 to 3.44, with all HC3 P values below 0.05. The signal, in short, was not carried by any one man’s blood sample.

Yet the study’s most instructive result may be the one that did not favor the ratio. When the authors compared a model built on testosterone alone against the estradiol-to-testosterone model using the Akaike information criterion, a statistic that balances goodness of fit against model complexity, the testosterone-based model fit maximum amplitude slightly better, with an AIC of 525.2 versus 526.2. The difference is small, but its direction matters: the ratio, despite its theoretical appeal as an integrated index of hormonal balance, did not add explanatory power beyond what testosterone already provided. The author’s conclusion is accordingly measured. The estradiol-to-testosterone ratio should be viewed as a descriptive index of relative androgen-estrogen balance rather than an established independent thrombotic biomarker, and the association with clot strength should be treated as hypothesis-generating pending prospective confirmation.

That caution is well placed given the study’s design and scope. A cross-sectional analysis captures a single moment in time and cannot determine whether hormonal imbalance drives clot strength, whether an underlying metabolic or inflammatory state influences both, or whether reverse causation is at work. The cohort was modest in size, confined to hospitalized men with type 2 diabetes at a single center, and the analysis was secondary, meaning it repurposed data collected for a parent study rather than being designed from the ground up to test the hormone-clot question. Hormone levels also fluctuate with time of day, acute illness, and assay characteristics, all of which can introduce noise in a hospitalized population. Prospective studies that follow men over time, measure hormones repeatedly, and track actual thrombotic events would be needed to establish whether the ratio, or testosterone itself, has genuine predictive or clinical value.

Even so, the research opens a tantalizing line of inquiry at the intersection of endocrinology and hematology. Sex hormones are known to influence vascular biology in multiple ways, from effects on platelet reactivity to endothelial function and fibrinolysis, and diabetes amplifies cardiovascular risk through overlapping metabolic and inflammatory pathways. If a simple, widely available hormone panel could one day help stratify thrombotic risk in diabetic men, it would offer an accessible complement to existing risk scores. For now, the message is one of disciplined curiosity: a higher estradiol-to-testosterone ratio tracks with stronger clots in this population, the association is statistically durable, but the ratio does not beat testosterone alone, and no one should change clinical practice on the basis of a single exploratory analysis. The next chapter of this story will be written by prospective studies designed to answer the question this work could only raise.

Subject of Research: Association between the estradiol-to-testosterone ratio and thromboelastographic clot strength in men with type 2 diabetes

Article Title: Estradiol-to-testosterone ratio versus testosterone in relation to thromboelastographic clot strength in men with type 2 diabetes: a secondary cross-sectional analysis

Article References: Chen, X.-J. (2026). Estradiol-to-testosterone ratio versus testosterone in relation to thromboelastographic clot strength in men with type 2 diabetes: a secondary cross-sectional analysis. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02545-y

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02545-y

Keywords: type 2 diabetes mellitus, estradiol-to-testosterone ratio, testosterone, thromboelastography, maximum amplitude, clot strength, hypercoagulability, cross-sectional analysis, hormonal balance, cardiovascular risk, statistical sensitivity analysis, Estradiol-to-testosterone

The core of the argument is deceptively simple. A platelet count tells you how many platelets are circulating, but says nothing about whether they work. Platelets contribute to hemostasis through adhesion, activation, granule release, aggregation, and support of thrombin generation, and none of these functions is captured by a routine count. Multiple studies have now documented profound platelet dysfunction in patients with traumatic brain injury even when their counts sit comfortably within the normal range. The authors define this dysfunction as a measurable impairment in agonist-induced aggregation, in the responsiveness of specific receptor pathways, or in the platelet’s contribution to whole-blood clot strength, occurring disproportionately to or entirely in the absence of thrombocytopenia. In other words, a patient can have plenty of platelets and still have platelets that fail.

The biological explanation lies in the unique nature of brain injury. When neural tissue is disrupted, it releases tissue factor, damage-associated molecular patterns, microparticles, and lipid mediators into the circulation, triggering thrombin generation, platelet activation, and ultimately receptor desensitization. The result is a paradoxical hemostatic state the authors describe as activation exhaustion: early procoagulant activation coexists with downstream hyporesponsiveness. Platelet activation and platelet dysfunction, far from being mutually exclusive, appear to be overlapping temporal phases of the same post-injury response. This may explain a frustrating clinical pattern in which patients with traumatic brain injury suffer early hemorrhagic progression of their intracranial lesions and later develop thrombotic complications, two seemingly opposite outcomes arising from the same underlying biology.

The strongest mechanistic evidence comes from a study by Castellino and colleagues, who examined 70 patients with isolated head injury, carefully excluding hemorrhagic shock, hypotension, and antiplatelet medication use. In severe traumatic brain injury, they found adenosine diphosphate, or ADP, pathway inhibition of 93.1 percent, with an interquartile range of 44.8 to 98.3 percent, compared with just 15.5 percent in controls, a difference that was highly statistically significant, and the arachidonic acid pathway was involved concurrently. A parallel rat model confirmed ADP inhibition of 77.6 percent, plus or minus 6.7 percent, just 15 minutes after injury. These findings establish that brain injury alone, independent of systemic hemodynamic compromise, generates profound receptor-level platelet dysfunction, a mechanism distinct from pharmacological blockade and from inhibition driven by circulating mediators.

Current clinical guidelines recommend maintaining platelet counts above 50 billion per liter in active intracranial hemorrhage and above 100 billion per liter around surgery. Those thresholds remain essential, the authors stress, but they address only quantity. A patient whose count is well above both limits may still harbor significant dysfunction at the level of the ADP/P2Y12 or arachidonic acid/cyclooxygenase-1 receptor pathways. The authors also warn against two opposite errors: equating thrombocytopenia with platelet failure, and treating any detected dysfunction as an automatic indication for transfusion. Their framework rests on three clinical questions: which phenotype is present, is it clinically meaningful, and can correcting it actually improve outcomes?

Detecting these phenotypes requires functional testing, and here the landscape is complicated. Standard coagulation tests, including prothrombin time, international normalized ratio, and fibrinogen measurement, are essentially blind to platelet function. Viscoelastic assays such as thromboelastography and rotational thromboelastometry assess whole-blood clot kinetics and strength, and platelet mapping modules add agonist-specific response data. Other platforms, including Multiplate, VerifyNow, and light transmission aggregometry, measure different biological parameters and cannot be directly compared with one another. Cross-platform equivalence in traumatic brain injury has not been established, and the most frequently cited working thresholds, ADP or arachidonic acid inhibition greater than 60 percent on thromboelastography with platelet mapping, were never prospectively validated. They represent observational approximations, not clinical standards, and no universally accepted intervention cutoffs exist for any platform.

The therapeutic evidence is strikingly discordant, and the authors argue that the discordance follows a pattern rather than being random. On the positive side, one retrospective series found that goal-directed platelet transfusion guided by platelet mapping in severe traumatic brain injury was associated with lower mortality, and a platelet mapping algorithm reduced transfusion exposure without apparent harm in patients exposed to antiplatelet drugs. Against this, multiple studies found no benefit and potential harm from empirical platelet transfusion or desmopressin in less severely injured populations or when treatment was not guided by functional testing. The positive studies were conducted in severe injury with documented profound dysfunction and function-guided decisions; the negative studies applied empirical treatment in milder populations. The lesson, the authors conclude, is that intervention should be phenotype-guided and risk-stratified, not routine and empirical.

The risks of getting this wrong are not trivial. Platelet transfusion carries the danger of transfusion-associated circulatory overload, transfusion-related acute lung injury, alloimmunization, and prothrombotic complications, while desmopressin, typically dosed at 0.3 to 0.4 micrograms per kilogram intravenously in structured protocols, can cause hyponatremia, fluid retention, and thrombosis. The authors frame their recommendation through the lens of patient blood management: the question is not whether platelets are good or bad, but whether a clinically relevant, modifiable phenotype exists in which intervention is likely to change meaningful outcomes. They propose a five-category taxonomy matching platelet-related phenotypes to clinical context, dominant mechanism, and therapeutic implication, while candidly noting that this construct is expert-synthesized and has not been prospectively validated as a diagnostic classification system.

The practical approach they sketch is deliberately cautious. Platelet function testing is most defensible in moderate-to-severe injury, traumatic intracranial hemorrhage, radiological progression, planned neurosurgery or invasive neuromonitoring, known preinjury antiplatelet exposure, systemic polytrauma with coagulopathy, or unexplained bleeding despite a normal count. When function is preserved, empirical reversal should generally be avoided. When dysfunction is documented in high-risk patients requiring surgery or invasive monitoring, desmopressin or platelet transfusion may be considered according to phenotype, antiplatelet exposure, count, and procedural urgency, with post-intervention reassessment by clinical status, imaging, and repeat functional testing. Centers without access to viscoelastic platforms can fall back on clinical risk stratification using the Glasgow Coma Scale, lesion subtype, antiplatelet exposure, and procedural urgency, consistent with American College of Surgeons guidance. In emergent surgical scenarios, urgency simply overrides testing; in nonemergent settings, a 30-to-60-minute window permits targeted hemostatic preparation.

The authors are explicit about the limits of their case. Most clinical evidence is observational, retrospective, or single-center; interassay discordance remains a fundamental barrier; dysfunction rarely occurs in isolation and overlaps with fibrinogen abnormalities, acidosis, hypothermia, hypocalcemia, and hemodilution; the dynamic evolution of dysfunction over the first 72 hours is poorly characterized; and findings from moderate-to-severe cohorts cannot be extrapolated to mild injury. Many studies report laboratory correction without demonstrating improved patient outcomes. What they call for is a new generation of prospective, multicenter trials to determine which assay best identifies clinically meaningful dysfunction, which threshold predicts hemorrhagic progression, and whether phenotype-guided correction improves neurological outcomes rather than merely normalizing laboratory values. In neurocritical care, they write, what is hidden beyond the platelet count may be clinically decisive, and the next step is not simply to transfuse more platelets but to understand which platelet phenotype matters, when it matters, and how it can be safely corrected.

Subject of Research: Platelet dysfunction as a hemostatic phenotype in traumatic brain injury coagulopathy

Article Title: Rethinking Platelet Dysfunction in Traumatic Brain Injury: From Platelet Count to Hemostatic Phenotype

Article References: Quintana Diaz, M., & Godoy, D. A. (2026). Rethinking Platelet Dysfunction in Traumatic Brain Injury: From Platelet Count to Hemostatic Phenotype. Neurocritical Care. https://doi.org/10.1007/s12028-026-02670-5

Image Credits: AI Generated

DOI: 10.1007/s12028-026-02670-5

Keywords: traumatic brain injury, platelet dysfunction, coagulopathy, hemostatic phenotype, thromboelastography, platelet mapping, platelet transfusion, desmopressin, intracranial hemorrhage, neurocritical care, patient blood management, P2Y12 pathway

The review, led by Ali Msheik of Hamad Medical Corporation in Doha, Qatar, together with colleagues in trauma surgery, neurocritical care, and medical ethics, synthesized all available systematic reviews of viscoelastic hemostatic assays in neurocritical illness. These assays, which include thromboelastography known as TEG, TEG Platelet Mapping, and rotational thromboelastometry known as ROTEM, differ fundamentally from standard coagulation tests. Instead of isolating plasma and timing a single clotting reaction, they measure the actual physical behavior of clot formation in whole blood: how quickly the clot initiates, how strongly it propagates, how firm the final clot becomes, and how readily fibrinolysis breaks it down. In principle, this gives clinicians a real-time picture of hemostasis that standard tests cannot capture.

To assess the accumulated evidence, the researchers followed PRISMA 2020 reporting guidelines, the Joanna Briggs Institute manual for umbrella reviews, and MOOSE recommendations, searching PubMed, Embase, Scopus, the Cochrane Library, and Web of Science from database inception to January 2026. Two physician reviewers with experience in neurocritical care independently screened records, extracted data, and appraised methodological quality. The screening funnel was dramatic: of 272 records identified, 199 were screened after duplicate removal, and only four systematic reviews survived full-text assessment. The authors emphasized that this narrowing reflects the strict restriction to review-level evidence with reproducible methods and extractable neuro-specific data, not a post hoc reshaping of the question.

Those four reviews encompassed 73 study occurrences representing 63 unique primary studies, spanning traumatic brain injury, subarachnoid hemorrhage, and mixed populations with ischemic stroke and coronary artery disease. A corrected covered area analysis quantified how much the underlying evidence overlapped, finding only slight overall redundancy at 5.3 percent. Within traumatic brain injury, however, the two dedicated reviews shared 12 primary studies, a corrected covered area of 29.4 percent, while the subarachnoid hemorrhage and antiplatelet therapy reviews shared no studies with other clusters. This low overall overlap means the field is not merely recycling the same small trials, an encouraging sign for the maturity of the evidence base even as quality concerns remain.

The methodological appraisal revealed uneven rigor. Using AMSTAR-2, a validated tool for assessing systematic reviews, only one review, a 2021 meta-analysis of thromboelastography in traumatic brain injury by Cannon and colleagues, achieved moderate confidence, supported by a registered protocol, a comprehensive search, duplicate screening, and structured bias assessment. The remaining reviews earned low or critically low confidence ratings owing to absent protocols, incomplete reporting of excluded studies, and limited transparency. When the authors then applied GRADE criteria to rate certainty in individual outcomes, most estimates in traumatic brain injury and subarachnoid hemorrhage fell to low or very low certainty, a consequence of predominantly observational designs, inconsistent definitions, and imprecise effects.

Within those constraints, the prognostic signal was remarkably consistent. Across two reviews covering 32 unique studies in traumatic brain injury, viscoelastic assays repeatedly identified clinically relevant coagulation disturbances. Abnormal clot strength and disturbed fibrinolytic activity were associated with mortality across 18 observational studies, with radiographic hemorrhage progression in 14 studies, and with the need for neurosurgical intervention in nine, though confounding and heterogeneous outcome definitions limited those latter findings. In subarachnoid hemorrhage, a single review of 19 primary studies found that hypercoagulable profiles, particularly increased clot firmness, were consistently linked to delayed cerebral ischemia in six studies and to early brain injury severity in four. These associations make biological sense: dysregulated clot formation and breakdown plausibly contribute to secondary brain injury, hemorrhage expansion, and delayed ischemia after aneurysm rupture.

The therapeutic story was different. No review provided convincing evidence that viscoelastic-guided interventions improved outcomes in traumatic brain injury or subarachnoid hemorrhage, meaning the assays currently function as crystal balls rather than steering wheels in these conditions. The one bright spot came from mixed ischemic populations: moderate-certainty evidence from a meta-analysis of ten studies, including randomized trials, suggested that TEG-guided antiplatelet therapy in patients with ischemic stroke and coronary artery disease was associated with fewer composite ischemic and bleeding events than standard care. Mortality effects, however, remained uncertain because reporting was sparse and inconsistent, and because the population blended cardiac and cerebrovascular patients, the finding cannot be directly transferred to pure stroke care without further validation.

The authors are explicit about what this means for practice. Viscoelastic assays, they conclude, may be most appropriately used as adjunctive diagnostic and prognostic tools in neurocritical care rather than as standalone guides for transfusion or hemostatic treatment decisions in brain trauma and aneurysmal hemorrhage. The finding challenges a seductive assumption, one that has driven adoption in trauma and cardiac surgery, that simply identifying a coagulation disturbance and acting on it automatically improves outcomes. In the neurocritical setting, the leap from detection to benefit has not yet been demonstrated in rigorous trials, and current clinical guidelines accordingly do not recommend routine viscoelastic testing in these populations.

Several structural obstacles help explain the gap between prognostic promise and therapeutic proof. Included studies frequently came from single centers using institution-specific protocols, with inconsistent assay platforms, variable clinical cutoffs, and differing transfusion and antiplatelet practices. Without harmonized thresholds and standardized definitions of what counts as an actionable abnormality, clinicians cannot translate an abnormal tracing into a uniform treatment decision, and trialists cannot pool results meaningfully. These limitations reduce generalizability and complicate the interpretation of every association reported to date.

The research agenda that follows is clear. The authors call for large prospective neuro-specific cohorts using standardized viscoelastic thresholds, randomized trials testing VHA-guided transfusion or reversal strategies specifically in traumatic brain injury and subarachnoid hemorrhage, harmonization of assay parameters and clinical definitions, mechanistic studies linking viscoelastic abnormalities to neurovascular pathophysiology, and targeted evaluation of TEG-guided antiplatelet therapy in stroke populations alone. Until that work is done, the review suggests, clinicians and policymakers should read abnormal viscoelastic findings as important prognostic information, valuable for risk stratification and communication, while resisting the temptation to build treatment algorithms on evidence that has yet to bear their weight. For a technology that has already transformed hemostasis management in trauma and cardiac surgery, neurocritical care remains the unfinished frontier.

Subject of Research: Viscoelastic hemostatic assays for prognosis and treatment guidance in neurocritical illness

Article Title: The utility of viscoelastic hemostatic assays in neurocritical illness

Article References: Msheik, A., Peralta, R., Al-Rumaihi, G., Rizoli, S., Al Mokdad, Z., de Oliveira Manoel, A. L., & Al-Thani, H. (2026). The utility of viscoelastic hemostatic assays in neurocritical illness. Journal of Emergency and Disaster Medicine, 2(1), Article 10. https://doi.org/10.1007/s44467-026-00012-1

Image Credits: AI Generated

DOI: 10.1007/s44467-026-00012-1

Keywords: viscoelastic hemostatic assays, thromboelastography, ROTEM, traumatic brain injury, subarachnoid hemorrhage, ischemic stroke, coagulopathy, neurocritical care, umbrella review, antiplatelet therapy, delayed cerebral ischemia, GRADE evidence